A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.

Diabetologia
Julio RosenstockG Schernthaner

Abstract

This 52-week multinational, randomised, open-label, parallel-group, non-inferiority trial compared clinical outcomes following supplementation of oral glucose-lowering drugs with basal insulin analogues detemir and glargine in type 2 diabetic patients. Insulin-naive adults (n=582, HbA(1c) 7.5-10.0%, BMI <or= 40.0 kg/m(2)) were randomised 1:1 to receive insulin detemir or glargine once daily (evening) actively titrated to target fasting plasma glucose (FPG) <or= 6.0 mmol/l. An additional morning insulin detemir dose was permitted if pre-dinner plasma glucose (PG) was >7.0 mmol/l after achieving FPG <7.0 mmol/l. Due to labelling restrictions, no second glargine dose was allowed. Baseline HbA(1c) decreased from 8.6 to 7.2 and 7.1% (NS) with detemir and glargine, respectively. FPG improved from 10.8 to 7.1 and 7.0 mmol/l (NS), respectively. With detemir, 45% of participants completed the study on once daily dosing and 55% on twice daily dosing, with no difference in HbA(1c). Overall, 52% of participants achieved HbA(1c) <or= 7.0%: 33% (detemir) and 35% (glargine) without hypoglycaemia. Within-participant variability for self-monitored FPG and pre-dinner PG did not differ by insulin treatment, nor did the relative risk of overall or...Continue Reading

References

Aug 14, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·M Korytkowski
Aug 14, 2002·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·M Marre
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators
Mar 12, 2004·The American Journal of Medicine·Matthew C Riddle
Aug 13, 2004·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·M Davies
Nov 10, 2004·Diabetes Research and Clinical Practice·K RaslováN Hâncu
Feb 2, 2006·Expert Opinion on Pharmacotherapy·Philip Home, Peter Kurtzhals
May 24, 2006·Archives of Medical Research·Freddy G EliaschewitzUNKNOWN HOE 901/4013 LA Study Group
Mar 30, 2007·Diabetes, Obesity & Metabolism·K Hermansen, M Davies
Oct 11, 2007·Diabetes, Obesity & Metabolism·David Russell-Jones, Rehman Khan

❮ Previous
Next ❯

Citations

Feb 17, 2010·Diabetologia·A M Wägner, D Mauricio
Sep 10, 2008·Current Diabetes Reports·Osama Hamdy, Catherine Carver
Oct 30, 2012·Endocrine·Luigi F Meneghini
Mar 5, 2009·Advances in Therapy·Jean-Louis Selam, Luigi F Meneghini
Oct 11, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Akram EchtayBracha Dagan
Apr 17, 2010·Primary Care Diabetes·Luigi MeneghiniMartin J Abrahamson
Jul 3, 2008·Nature Clinical Practice. Endocrinology & Metabolism·Jennifer B Marks
Sep 23, 2008·Nature Clinical Practice. Endocrinology & Metabolism·Christoph Koenen
Aug 22, 2008·Diabetes Technology & Therapeutics·Satish K Garg, Ramachandra G Naik
May 18, 2010·Diabetes Technology & Therapeutics·Alan C Moses, Christoph Koenen
Sep 3, 2010·Diabetes Technology & Therapeutics·Frits Holleman, J Hans DeVries
Jun 28, 2011·Diabetes Technology & Therapeutics·F Javier Ampudia-BlascoJuan F Ascaso
Jun 28, 2011·Diabetes Technology & Therapeutics·Stuart LittlePhilip Home
Jun 28, 2011·Diabetes Technology & Therapeutics·Maka S HedringtonStephen N Davis
Aug 26, 2011·Diabetes Technology & Therapeutics·Geremia B BolliEllie S Strock
Apr 30, 2013·Diabetes Technology & Therapeutics·Yoshio NagaiYasushi Tanaka
Mar 18, 2011·Metabolic Syndrome and Related Disorders·Katherine EspositoDario Giugliano
Jan 25, 2013·The Nurse Practitioner·Betsy B Dokken
Mar 10, 2009·Diabetes, Obesity & Metabolism·M MonamiE Mannucci
Jan 30, 2009·Diabetes, Obesity & Metabolism·Mariëlle J P van Avendonk, Guy E H M Rutten
Jan 16, 2009·International Journal of Clinical Practice·A BarnettN Munro
Oct 5, 2010·Journal of Obesity·Vicky Cheng, Sangeeta R Kashyap

❮ Previous
Next ❯

Software Mentioned

LANMET
SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.